Ma Jie, Zhu Huimin, Li Ling, Ma Hui, Zheng Bo
Department of Hematology, General Hospital of Ningxia Medical University, Yinchuan City, China.
Ningxia rehabilitation medical center, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan City, China.
Womens Health Rep (New Rochelle). 2025 Feb 3;6(1):147-154. doi: 10.1089/whr.2024.0164. eCollection 2025.
The hematological malignancies during pregnancy are rare and lethal.
The aim of this study is to demonstrate the incidence, clinical characteristics, treatment, and outcome of hematological malignancies diagnosed during pregnancy.
This is a retrospective study of women who were diagnosed with hematological malignancies during pregnancy at an academic hospital between 2001 and 2021.
The incidence rate of 26 pregnant women with hematological malignancies in the pregnant patients admitted to the hospital was about 0.07%. Except for one patient who was diagnosed before pregnancy, the incidence rates of the first, second, and third trimesters of pregnancy were 12% (3/25), 48% (12/25), and 40% (10/25), respectively. Eleven out 26 patients (42.3%) finally gave birth to fetuses. In a long-term follow-up, the survival time of patients with leukemia in pregnancy was shorter than lymphoma ( < 0.05).
This report provides a comprehensive description of maternal and infant outcomes and insights into the management of hematological malignancies during pregnancy.
孕期血液系统恶性肿瘤罕见且致命。
本研究旨在阐明孕期诊断出的血液系统恶性肿瘤的发病率、临床特征、治疗及结局。
这是一项对2001年至2021年期间在一家学术医院孕期被诊断为血液系统恶性肿瘤的女性进行的回顾性研究。
在入院的孕妇中，26例患有血液系统恶性肿瘤的孕妇发病率约为0.07%。除1例在妊娠前被诊断外，妊娠第一、第二和第三孕期的发病率分别为12%（3/25）、48%（12/25）和40%（10/25）。26例患者中有11例（42.3%）最终产下胎儿。在长期随访中，孕期白血病患者的生存时间短于淋巴瘤患者（<0.05）。
本报告全面描述了母婴结局，并为孕期血液系统恶性肿瘤的管理提供了见解。
